Ftse Mib
33.736,40
-0,03%
DAX
17.896,50
-0,14%
S&P 500
5.064,20
0,91%
NASDAQ
15.840,96
1,51%
Bitcoin
59.707,78
0,99%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Vaxart Inc (VXRT) Vaxart Inc (VXRT) Notizie

Vaxart Inc

VXRT
0,74
0,0394 (5,62%)
03 Mag 2024 - Chiuso
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
30/4/202414:00GLOBEVaxart Announces Positive Results for Its Bivalent Norovirus..
27/3/202413:00GLOBEVaxart to Present at World Vaccine Congress Washington 2024..
20/3/202413:00GLOBEVaxart, Inc. Reports Inducement Grants Under Nasdaq Listing..
14/3/202421:01GLOBEVaxart Provides Business Update and Reports Full Year 2023..
14/3/202412:41IHMARKETNEWSU.S. Stock Futures Rise Ahead Of PPI and Retail Sales; Oil..
07/3/202414:00GLOBEVaxart to Host Full Year 2023 Business Update and Financial..
06/3/202415:23EDGAR2Form 8-K - Current report
06/3/202414:00GLOBEVaxart, Inc. Appoints Steven Lo as President, Chief..
29/2/202422:30EDGAR2Form 8-K - Current report
15/2/202422:10EDGAR2Form 8-K - Current report
13/2/202423:16EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
05/2/202414:00GLOBEVaxart Announces Publication in Vaccines of Non-Human..
02/2/202422:49EDGAR2Form 8-K/A - Current report: [Amend]
19/1/202423:14EDGAR2Form 8-K - Current report
19/1/202422:30EDGAR2Form SC 13G - Statement of acquisition of beneficial..
19/1/202414:30GLOBEVaxart Receives $9.27 Million BARDA Project NextGen Award to..
16/1/202423:18EDGAR2Form 8-K - Current report
16/1/202415:25GLOBEVaxart Announces $10.0 Million Registered Direct Offering..
16/1/202415:22GLOBEVaxart, Inc. Announces Management Change
16/1/202415:19EDGAR2Form 8-K - Current report
21/12/202314:00GLOBEVaxart Announces Last Subject Dosed in Phase 1 Trial of Its..
02/11/202321:16EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
02/11/202321:11EDGAR2Form 8-K - Current report
02/11/202321:01GLOBEVaxart Provides Business Update and Reports Third Quarter..
02/11/202313:00GLOBEVaxart Doses First Subject in Phase 1 Trial of Its Norovirus..
26/10/202314:00GLOBEVaxart to Host Third Quarter 2023 Business Update and..
23/10/202323:09EDGAR2Form 8-K/A - Current report: [Amend]
23/10/202323:01EDGAR2Form 8-K - Current report
11/10/202314:00GLOBEVaxart to Present at World Vaccine Congress Europe 2023 on..
21/9/202314:00GLOBEVaxart to Participate in Fireside Chat at 2023 Cantor Global..
06/9/202322:43EDGAR2Form 8-K - Current report
06/9/202322:05GLOBEVaxart Announces Topline Data from the Phase 2 Challenge..
03/8/202322:30EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
03/8/202322:20EDGAR2Form 8-K - Current report
03/8/202322:01GLOBEVaxart Provides Business Update and Reports Second Quarter..
02/8/202303:23EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/8/202303:20EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/8/202303:16EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/8/202303:14EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/8/202302:49EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27/7/202314:00GLOBEVaxart to Host Second Quarter 2023 Business Update and..
26/7/202322:20EDGAR2Form 8-K - Current report
10/7/202322:12EDGAR2Form 8-K - Current report
06/7/202314:00GLOBEVaxart Announces Positive Preliminary Topline Data from..
28/6/202322:22EDGAR2Form 8-K - Current report
26/6/202322:45GLOBEVaxart Stockholders Approve All Four Proposals in the 2023..
21/6/202322:30GLOBEVaxart Encourages All Stockholders of Record as of April 28,..
07/6/202315:16GLOBEVaxart, Inc. Announces Pricing of $15,000,000 Public..
06/6/202322:01GLOBEVaxart, Inc. Announces Proposed Public Offering of Common..
06/6/202314:00GLOBEVaxart Announces Last Subject Dosed in Phase 2 Trial of its..
Apertura: 0,7182 Min: 0,69 Max: 0,7469
Chiusura: 0,7006

La tua Cronologia

NASDAQ
VXRT
Vaxart
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network